Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study by Daoussis, Dimitrios et al.
Original article
Experience with rituximab in scleroderma: results
from a 1-year, proof-of-principle study
Dimitrios Daoussis
1,*, Stamatis-Nick C. Liossis
1,*, Athanassios C. Tsamandas
2,
Christina Kalogeropoulou
3, Alexandra Kazantzi
3, Chaido Sirinian
2,
Maria Karampetsou
1, Georgios Yiannopoulos
1 and Andrew P. Andonopoulos
1
See page 201 for the editorial comment on this article (doi:10.1093/rheumatology/kep421)
Abstract
Objective. To assess the efficacy of rituximab (RTX) in SSc.
Methods. Fourteen patients with SSc were evaluated. Eight patients were randomized to receive two
cycles of RTX at baseline and 24 weeks [each cycle consisted of four weekly RTX infusions (375mg/m
2)]
in addition to standard treatment, whereas six patients (control group) received standard treatment alone.
Lung involvement was assessed by pulmonary function tests (PFTs) and chest high-resolution CT (HRCT).
Skin involvement was assessed both clinically and histologically.
Results. There was a significant increase of forced vital capacity (FVC) in the RTX group compared with
baseline (mean  S.D.: 68.13 19.69 vs 75.63 19.73, at baseline vs 1-year, respectively, P¼0.0018). The
median percentage of improvement of FVC in the RTX group was 10.25%, whereas that of deterioration
in the controls was 5.04% (P¼0.002). Similarly, diffusing capacity of carbon monoxide (DLCO) increased
significantly in the RTX group compared with baseline (mean  S.D.: 52.25 20.71 vs 62 23.21, at base-
line vs 1-year respectively, P¼0.017). The median percentage of improvement of DLCO in the RTX group
was 19.46%, whereas that of deterioration in the control group was 7.5% (P¼0.023). Skin thickening,
assessed with the Modified Rodnan Skin Score (MRSS), improved significantly in the RTX group com-
pared with the baseline score (mean  S.D.: 13.5 6.84 vs 8.37 6.45 at baseline vs 1-year, respectively,
P<0.001).
Conclusion. Our results indicate that RTX may improve lung function in patients with SSc. To confirm our
encouraging results we propose that larger scale, multicentre studies with longer evaluation periods
are needed.
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Introduction
SSc is a chronic systemic autoimmune disease character-
ized by vasculopathy and progressive fibrosis. SSc—
interstitial lung disease (ILD)—is not uncommon in
patients with the diffuse form of the disease and repre-
sents the clinical manifestation that dictates prognosis;
this manifestation responds poorly to treatment.
Therapeutic options for treating SSc-associated ILD are
limited and most of the drugs tested so far have shown
poor or modest results. Cyclophosphamide (CYC) has
shown statistically significant but clinically questionable
efficacy in the treatment of SSc-associated ILD, but is
associated with immunosuppression underscoring the
necessity for novel, more effective and less toxic therapies
[1–4]. We and others [5–7] have employed mycophenolate
mofetil (MMF) in the treatment of a limited number of
patients with SSc-related ILD with encouraging, yet
preliminary, results.
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candidate therapy for SSc, since several lines of evidence
point in the direction of B cells having a possible patho-
genic role in this debilitating disease [8, 9]. B cells from
tight skin mice—an animal model of SSc—exhibit chronic
hyperactivity and exaggerated calcium responses after
B-cell receptor (BCR) cross-linking. B cells from this
animal model show augmented CD19 (an important
positive BCR response regulator) signalling caused by
impaired function of CD22, a negative BCR response
regulator [10]. Likewise, B cells from patients with SSc
overexpress CD19, compared with B cells from healthy
subjects and disease control patients, and are chronically
activated [11]. Furthermore, studies revealed that B-cell
genes were specifically transcribed in SSc skin [12] and
that B-cell infiltration was a prominent feature of
SSc-associated ILD [13].
Rituximab (RTX) is a chimeric mAb against human CD20
that depletes peripheral B cells. It has been successfully
introduced in the treatment of systemic rheumatic
diseases and exhibits an acceptable safety profile. In
animal models of SSc, administration of anti-CD20 mAb
to newborn tight skin mice led to significant suppression
of skin fibrosis [14]. On the other hand, there are encoura-
ging data from the literature regarding the use of RTX in
chronic graft vs host disease (GVHD) [15–18]. GVHD is
a late complication of heterologous haematopoietic
stem-cell transplantation and exhibits several similarities
to SSc, such as scleroderma-like skin manifestations and
circulating autoantibodies. Furthermore, chronic GVHD
has been considered by some as a systemic autoimmune
disease [19–22]. The observed microchimerism in a
significant percentage of patients with SSc may further
suggest pathogenetic similarities between the two
entities, justifying similar therapeutic trials [23, 24].
Recently, two uncontrolled studies have explored the
potential clinical efficacy of RTX in SSc. In the first one,
skin fibrosis as assessed clinically and histologically
improved significantly in the RTX-treated patients [25].
In the second one, even though no overt clinical benefit
was observed, skin biopsies from RTX-treated patients
exhibited a significant reduction in the myofibroblast
score and the patients remained clinically stable through-
out the study period [26]. There are also two additional
reports (in abstract form) showing improvement of skin
fibrosis (27, 28) and a case report of improvement of
SSc-associated ILD (29). The preliminary encouraging
results from the use of RTX in animal models of SSc
and in humans with chronic GVHD and SSc has led us
to investigate more thoroughly the potential efficacy of
RTX in patients with SSc in an open-label, proof-of-
principle, randomized, controlled study. We report herein
that RTX treatment of patients with SSc and SSc-
associated ILD led to improvement of lung function and
was well tolerated.
Patients and methods
Patients
We enrolled 14 patients with a diagnosis of SSc, fulfilling
the preliminary ACR criteria for the classification of the
disease (30). Baseline demographic and clinical charac-
teristics of the patients are presented in Table 1. All
patients underwent a complete physical examination
and a detailed review of their medical records prior to
study enrolment. Other variables were also evaluated
(full blood count, biochemistry profile, autoantibody
profiles, urinalysis, ECG and cardiac ultrasound).
Inclusion criteria were: (i) the detection of anti-Scl-70
autoantibodies in their sera; (ii) the presence of SSc-
associated ILD as indicated by findings in either high-
resolution CT (HRCT) of the chest or pulmonary function
tests (PFTs) or both; and (iii) the absence of any changes
in medications and/or dosage of treatment administered
during the last 12 months before enrolment. All patients
belonged to the diffuse variety of the disease as docu-
mented by the clinical presentation of skin involvement
at the time of the study and/or its course over time
since diagnosis. Moreover, all patients were anti-Scl-70
positive and had significant ILD, a feature of diffuse
SSc. No changes in medication were allowed during
the study.
A local (Patras University Hospital, Patras, Greece)
ethics committee approved the study (which fulfilled the
Declaration of Helsinki requirements) and a written
informed consent was obtained from all participating
individuals.
TABLE 1 Baseline characteristics of RTX and control group
RTX Control P-value
Age, median (range), years 53 (41–66.5) 56 (47.7–68.5) NS
Disease duration,
mean  S.D., years
6.87 4.88 8.33 5.6 NS
HAQ-DI, median (range) 0.687 (0.28–1.25) 0.312 (0.09–0.90) NS
MRSS, mean  S.D. 13.5 6.84 11.5 2.16 NS
FVC, mean  S.D. 68.13 19.69 86 19.57 NS
DLCO, mean  S.D. 52.25 20.71 65.33 21.43 NS
HRCT score, mean  S.D. 13.1 4.5 16.4 6.4 NS
FVC and DLCO are expressed as a percentage of normal predicted values based on age, sex and height.
HAQ-D1: HAQ-disability index; MRSS: Modified Rodnan Skin Score; NS: non-significant.
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Patients born on an even-numbered date (n¼8) were
assigned to the RTX group and those born on an odd-
numbered date (n¼6) to the control group. Patients in
the RTX group received four weekly pulses of RTX
(375mg/m
2) at baseline and at 6 months on top of the
already administered treatment. Patients in the control
group continued their previously administered treatment
unchanged (details in Table 2). Four patients in the RTX
group (Patients 2, 4, 5 and 6) and two in the control group
(Patients 11 and 14) were on MMF therapy during study
enrolment and remained so throughout the study.
They have been on that therapy for at least 4 years prior
to study enrolment (apart from Patient 14 who was on
MMF therapy for 2 years prior to enrolment). Three
patients in the RTX group (Patients 2, 3 and 4) and one
in the control group (Patient 10) had received CYC in the
past but were off that therapy for at least 3 years prior to
study enrolment. There were no significant differences
between the two patient groups as shown in Table 2.
PFT
Standard PFTs were performed, at baseline, at 24 weeks
and at 1 year in all patients, including assessments of
forced vital capacity (FVC), forced expiratory volume in
the first second (FEV1), total lung capacity and diffusing
capacity of carbon monoxide (DLCO) corrected for haemo-
globin concentration. PFT parameters are expressed as
a percentage of normal predicted values based on age,
sex and height. All tests were performed at the same
laboratory, at our institution (Patras University Hospital).
Chest HRCT
All patients had an HRCT performed at baseline and at
24 weeks using a 16 multi-detector GE CT Scan (General
Electric, Waukesha WI, USA) with slice thickness of
0.625mm. Imaging findings were interpreted separately
by two experienced radiologists (C.K. and A.K.) in a
blinded fashion. Acquisition parameters of tube voltage,
tube current and slice thickness were 140 kilovolt poten-
tial (kVp), 300mA and 0.625mm, respectively. In order to
obtain contiguous images of lung abnormalities, a second
low-dose scanning (120kV, 200mA) was performed with
slice thickness of 1.25mm, covering the whole thorax.
This protocol permitted data reconstruction and evalua-
tion of images in coronal and saggital levels using
multiplanar reformatting algorithm. The severity and
extent of lung involvement was assessed according to
the scoring system proposed by Warrick et al. [31] as
follows: one point was assigned to ground glass appear-
ance, two points to irregular pleural margins, three
to septal/subpleural lines, four to honeycombing and five
to subpleural cysts. The sum of points results in the
severity score (0–15 points). Extent score was calculated
giving 1 point when involvement of one to three lung
segments was present, 2 points for four to nine segments
and 3 points to more than 10 segments (0–15 points).
Total score was obtained by adding the two above
scores (0–30 points).
Clinical assessment ofskin thickening
The MRSS was used for clinical assessment of skin
thickening at baseline and at 1 year, by an experienced
assessor in a blinded fashion [32, 33].
Skin histology
Histological assessment of skin fibrosis was made by skin
biopsies performed at baseline and at 24 weeks of
evaluation (a 5-mm punch biopsy of lesional skin). Skin
biopsies were performed in six patients of the RTX
group and three patients of the control group (including
those receiving CYC) and were performed prior to RTX
administration. Biopsies were taken from lesional skin
TABLE 2 Demographics, clinical and laboratory parameters of the cohort
Patient no./
sex/age
in years
Disease
duration,
years
FVC at
baseline
FVC at
1 year
DLCO
at
baseline
DLCO
at
1 year
MRSS
at
baseline
MRSS
at
1 year
Histological
improvement
Skin
B-cell
depletion
Concurrent
medications
RTX 1/F/47 6 85 88 67 78 14 10 No No Pred, Bos
2/M/72 5 55 62 40 49 8 2 Yes Yes Pred, MMF
3/F/56 6 70 75 33 38 10 4 Yes No Pred, Bos
4/M/39 13 30 35 14 27 29 21 Yes Yes Pred, Bos, MMF
5/F/33 15 85 90 71 96 16 14 No No Pred, MMF
6/F/56 7 90 97 67 67 12 4 Yes Yes MMF
7/F/70 1 68 84 64 81 11 8 NA NA –
8/F/50 2 62 74 62 60 8 4 NA NA Pred
Control 9/F/60 9 72 75 61 59 13 14 No No Pred, CYC
10/F/73 15 57 52 26 16 12 10 No No Pred
11/F/48 5 114 110 84 79 14 9 NA NA Pred, Bos, MMF
12/F/47 4 91 85 66 60 12 9 No No Bos, CYC
13/F/67 5 88 70 84 65 8 4 NA NA Pred
14/F/52 2 94 98 71 82 10 12 NA NA Pred, MMF
Pred: low-dose prednisone; Bos: Bosentan; NA: not applicable.
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RTX in sclerodermain the forearm; the second biopsy was taken from lesional
skin adjacent (always <2cm) to the site of the baseline
biopsy (supplementary Fig. 1, available as supplementary
data at Rheumatology Online).
Pathological evaluation of skin biopsies. All skin biopsies
were fixed in 10% neutral buffered formalin and
embedded in paraffin. Four micrometre-thick paraffin
sections were obtained and stained with haematoxylin
and eosin, and Masson’s trichrome (fibrosis evaluation).
All trichrome stains of biopsies were performed at the
same time, using the same staining set (04-011802-
Masson trichrome, Goldner-Bioptica, Milan, Italy) in
order to have comparable results.
Fibrosis quantification. To quantify collagen accumulation
in the dermis, we employed the Image J software (freely
downloadable and developed by Wayne Rasband at the
Research Services Branch of the NIH) according to the
method described previously [34]. A similarly and simulta-
neously stained skin biopsy from skin keloid was analysed
as well, representing a positive control for collagen
deposition. Collagen deposition was examined separately
for the papillary and the reticular dermis.
Evaluation of immunostains for the presence of B and
T cells. All biopsies were examined immunohisto-
chemically for the presence of T and B cells as described
previously using the BenchMark XT automated slide
stainer (Ventana, Tucson AZ, USA) and a standard strep-
tavidin biotin method [i view DAB-DAB MapTM Detection
kit (streptavidin horseradish peroxidase detection kit),
Ventana]. Antibodies used included: anti-CD4
(Neomarkers, Fremont CA, USA), anti-CD8 (Novocastra,
Newcastle, UK) and anti-CD20 (Dako, Carpinteria CA,
USA). As has been previously reported [35], 10 cell
counts were performed manually at  400 magnification
using a 10 10 microscope grid. Numbers of immuno-
chemically stained cells were determined by visual
inspection of three different fields per section. The
average scores then were calculated. All biopsies were
evaluated simultaneously in a blinded (to treatment
and date) fashion.
Overall functional impairment
We used the 20-item HAQ-DI [36, 37]. Clinically significant
improvement in functional status was defined as a 0.2
decrease in HAQ-DI score, as previously described [38].
Levels ofcirculating inter-cellular adhesion molecule-1,
E-selectin, vascular cell adhesion moleculeand ET-1
Serum samples were obtained from all patients at base-
line and at 24 weeks and were stored at  20 C. Serum
levels of the three soluble endothelium activation/injury
markers and of ET-1 were measured employing ELISA
methodology, using commercially available kits, accord-
ing to the manufacturer’s instructions (R&D Systems,
Minneapolis MN, USA).
Efficacy endpoints
Primary end points included evaluations of (i) changes in
pulmonary function as assessed by PFT and (ii) clinical
assessment of skin involvement by the MRSS.
Secondary outcome measures included changes in (i)
skin histology including collagen deposition and lympho-
cytic infiltration, (ii) HRCT scores, (iii) serum levels of
soluble markers and (iv) overall functional impairment.
Statistical analysis
Statistical analysis was performed using the SPSS
software (SPSS Inc., Chicago, IL, USA), version 14. Data
are presented as mean  S.D., median (upper and lower
quartile values) or percentages, as appropriate. The
paired Student’s t-test, Wilcoxon matched pairs test,
Mann–Whitney test and Fisher’s exact test were used
where indicated. Values of P<0.05 were considered as
statistically significant.
Results
Effects ofRTX treatment on SSc-associated ILD
PFTs and HRCT were used to assess the potential effect
of RTX administration on SSc-associated ILD.
PFTs improve following RTX treatment. At the 1-year
evaluation, there was a significant increase of FVC in the
RTX group compared with baseline (mean  S.D.:
68.13 19.69 vs 75.63 19.73, at baseline vs 1 year,
respectively, P¼0.0018), whereas no change was noticed
in the control group (mean  S.D.: 86 19.57 vs
81.67 20.69, at baseline vs 1 year, respectively,
P¼0.23), as shown in Fig. 1A and B. The median (upper
and lower quartile values) percentage of improvement
of FVC in the RTX group was 10.25% (6.19–18.65),
whereas in the control group FVC deteriorated [median
percentage of deterioration (upper and lower quartile
values) 5.04% (4.11–11.6)]. Direct comparison of FVC
changes recorded at 1 year revealed that the RTX-treated
group improved significantly (P¼0.002) compared with
the standard treatment (control) group.
There was a significant increase of DLCO in the RTX
group compared with baseline (mean  S.D.:
52.25 20.71 vs 62 23.21, at baseline vs 1 year, respec-
tively, P¼0.017), whereas no changes were noticed in the
control group (mean  S.D.: 65.33 21.43 vs 60.17 
23.69, at baseline vs 1 year, respectively, P¼0.25), as
shown in Fig. 1C and D. The median (upper and lower
quartile values) percentage of improvement of DLCO in
the RTX group was 19.46% (3.7–30.8), whereas in the
control group the median percentage of deterioration
was 7.5% (1.4–26.57) (P¼0.023).
The improvement of lung function tests in the RTX-
treated patients was already evident in the 24-week
evaluation (mean  S.D.: 71.5 21.3 and 55.2 25.1 for
FVC and DLCO, respectively).
Effects of RTX treatment on HRCT. HRCT scores were
identical at baseline and at 24 weeks in all patients in
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group, there was a modest increase in the HRCT score
that was not statistically significant (mean  S.D.:
16.4 6.4 vs 16.8 6.5, at baseline vs 24 weeks, respec-
tively, P¼0.170).
Effects ofRTX treatment on skin disease in patients
with SSc
To evaluate any potential effect of RTX on skin involve-
ment we performed standard clinical assessment and
skin biopsy analysis.
Effects of RTX treatment on skin thickening, as clinically
assessed. Skin thickening, assessed with the MRSS,
was similar in the two treatment groups at baseline
(Table 1, P¼0.50). However, at the 1-year evaluation,
there was a significant decrease of MRSS in the RTX
group compared with the baseline score (mean  S.D.:
13.5 6.84 vs 8.37 6.45 at baseline vs 1 year, respec-
tively, P¼0.0003). On the contrary, no significant change
in skin scores was noticed in the control group at 1 year
when compared with the baseline MRSS (mean  S.D.,
11.50 2.16 vs 9.66 3.38 at baseline vs 1 year, respec-
tively, P¼0.16). The median (upper and lower quartile
values) percentage of improvement in the RTX-treated
group was 39.25% (27.33–64.95) compared with
20.80% (10.78–39.28) in the control group. Statistical
analysis revealed that despite differences, the values
were not statistically significant (P¼0.06).
Effects of RTX treatment on collagen deposition. In the
RTX-treated group, there was a significant reduction of
collagen deposition in the papillary dermis at 24 weeks
compared with baseline (mean  S.D.: 51.75 19.78 vs
31.68 14.02 at Week 0 vs Week 24, respectively,
P¼0.030). The control group showed no change in
collagen deposition in the papillary dermis at 24 weeks
compared with baseline values (mean  S.D.: 46.53 
22.43 vs 46.27  10.49 at baseline vs Week 24, respec-
tively, P¼0.980). The median (upper and lower quartile
values) percentage of improvement of skin fibrosis in
the RTX group was 38.33% (6.86–59.9), whereas in the
control group skin fibrosis worsened (median percentage
of worsening of skin fibrosis was 5.23%). Histological
improvement was evident in four patients (Patients 2, 3,
4 and 6) of the RTX group and coincided with clinical
improvement in these patients (Table 2). Differences
were not statistically significant (P¼0.09). Representative
skin histology is shown in Figs 2 and 3.
When collagen deposition in the reticular dermis was
evaluated comparatively at baseline and at Week 24,
there were no differences either in the RTX (mean  S.D.:
76.57 16.04 vs 73.07 9.86 at Week 0 vs Week 24,
respectively, P¼0.758) or in the control group
(mean  S.D.: 50.97 28.88 vs 57.03 22.63 at Week 0
vs Week 24, respectively, P¼0.498) of patients with
SSc. Exceptionally, a striking improvement was observed
in Patient 2 (RTX group), who displayed a significant
reduction of skin fibrosis not only in the papillary but in
the reticular dermis as well, and had clinically an almost
FIG.1Effects of RTX treatment on PFTs. B-cell depletion treatment mediates a significant improvement of FVC
(P¼0.002) and DLCO (P¼0.023) at 1 year (A and C, respectively) compared with the values of the control group (B and
D). FVC and DLCO values are presented as percentages of predicted values.
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RTX in sclerodermacomplete resolution of sclerodermatous skin lesions
(Fig. 2C and D).
Effects of RTX on skin infiltrating B cells. The presence of
T and B cells was assessed by immunohistochemistry in
all biopsies. Representation of T cells was substantially
limited in all patients; these were predominantly CD8
þ
T cells and no differences were observed at 24 weeks,
compared with baseline (data not shown). The number
of B cells was relatively low as well, but they were more
abundant than T cells. RTX administration significantly
reduced the number of B cells in three patients (Patients
2, 4 and 6) but had no effect on the remaining
three patients of the RTX group (Patients 1, 3 and 5).
Patients exhibiting B-cell depletion in the skin following
RTX administration were the ones with the higher numbers
of B cells at baseline. All three patients with skin B-cell
depletion improved histologically. However, among the
three non-B-cell depletors, there was a single patient
who improved histologically (Patient 3). In the control
group no difference was recorded in B cell numbers at
24 weeks compared with baseline. All data and represen-
tative skin immunohistochemistry are shown in Fig. 4.
Overall functional impairment
There was a significant improvement in HAQ scores
at 1 year compared with baseline in the RTX group
FIG.2RTX-induced changes of skin histology at 24 weeks. Improvement of fibrosis in the papillary dermis of Patients 6
and 4 before and following RTX treatment (A, B and C, D, respectively). Improvement of fibrosis in full thickness dermis
(E and F) in Patient 2. Worsening of fibrosis at 24 week in full thickness dermis is seen in the control-treated Patient 8
(H) compared with baseline (G).
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FIG.3RTX-induced reduction of collagen deposition in the dermis (Masson’s trichrome X40) in Patients 4 (B) and 2 (D)
compared with baseline (A and C, respectively).
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(0.28–1.25) vs 0.312 (0.125–0.687) at baseline vs 1 year,
respectively, P¼0.03]. No change was noticed in the
control group [median (lower and upper quartile values),
0.312 (0.09–0.90) vs 0.125 (0.09–0.40) at baseline vs
1 year, respectively, P¼0.130]. In the RTX group, six
patients exhibited a clinically significant improvement of
functional status (as defined by a decrease of HAQ
score by 0.2) and two patients remained unchanged.
By contrast, in the control group one patient worsened,
two remained unchanged and three patients improved.
Markers of endothelium activation/injury andET-1
To examine any potential effects of RTX administration on
endothelium, which is a key player in SSc pathogenesis,
we measured serum levels of three markers of endothe-
lium activation/injury [E-selectin, vascular cell adhesion
molecule (VCAM) and inter-cellular adhesion molecule-1
(ICAM-1)] and ET-1. There was a trend towards a
decrease in all three endothelium activation/injury markers
and ET-1 serum levels in the RTX group at 24 weeks,
compared with baseline, which did not reach statistical
significance. It was worth noticing though that the patients
with histological improvement in skin biopsy (Patients 2, 3,
4 and 6) were the ones who displayed a decrease in
serum levels of at least three of the four markers studied.
In the control group, even though no statistically signifi-
cant changes were observed, VCAM and ET-1 levels
showed an upward trend at 24 weeks compared with
baseline (data not shown).
Adverse events
Patient 4 (RTX group) suffered a respiratory tract infection
3 months after the second cycle of RTX. The patient was
hospitalized for 3 days, treated with intravenous anti-
biotics and oxygen supplementation and recovered fully
in a few days.
Discussion
This is the first randomized controlled study in the litera-
ture to evaluate the efficacy of RTX in patients with SSc.
In this study, we report an improvement in lung function
with an increase in FVC and DLCO at 1 year, following two
cycles (composed of four weekly doses each) of RTX in
patients with SSc compared with the control group.
Perhaps more importantly, none of the RTX-treated
patients exhibited worsening of either FVC or DLCO,
whereas five out of six patients had declining FVC and
DLCO values at 1 year in the control group. These results
indicate that RTX may favourably affect lung function
parameters in patients with SSc. We should note,
however, that patients in the control group tended to
have more early disease and better lung function param-
eters (although not statistically different from the RTX
group) making them more likely to deteriorate over the
time of the study. Radiological assessment of ILD by
HRCT revealed no changes in the RTX group, whereas
there was a minor deterioration of two patients in the
control group. It is of importance to note that none of
the patients in the RTX group displayed worsening of
lung fibrosis assessed by HRCT. Therefore, our HRCT
studies support the idea that RTX treatment may stabilize
pulmonary lesions apparent on imaging in diffuse SSc.
The contrast between the RTX-induced improvement of
lung function and the lack of improvement in the imaging
studies may stem from using the Warrick scoring system,
which is a rather crude method of assessment, or
because the time interval of evaluation (24 weeks) was
too short. Alternatively, most of the lesions apparent on
HRCT may represent established fibrosis and not active
lesions even though the effects of RTX are incompletely
understood on both these parameters.
Although improvement in skin thickening, assessed by
MRSS, has been reported in some studies evaluating the
efficacy of different therapeutic agents in SSc, histological
confirmation of improvement has only been documented
following stem-cell transplantation [39]. Improvement of
skin fibrosis also occurs in the long term during the
FIG.4(A) Effects of RTX on skin infiltrating B cells.
Numbers of infiltrating B cells in the dermis (y-axis) at
baseline and at 24 weeks. The mean  S.D. of infiltrating
B cells was 5.41 3.73 vs 2.70 1.47at week 0 vs
week 24, respectively, P¼0.110 for the RTX group
and 5.69 2.16 vs 5.32 1.36 at week 0 vs week 24,
respectively, P¼0.54 for the control group. The arrows
indicate patients with histological evidence of
improvement of skin fibrosis. Apart from Patient 3,
in all other patients improvement of skin histology is
associated with RTX-induced decreases in the numbers
of skin-infiltrating B cells. (B) Elimination of skin-infiltrating
B cells of Patient 2 before (A) and following RTX (B) at
24 weeks.
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RTX in sclerodermaphysical course of the disease. In this study, improvement
of skin thickening, as assessed clinically, was evident in
the isolated analysis in the RTX group but head-to-head
comparisons with the control group revealed that differ-
ences strongly tended to reach statistical significance,
but did not reach it. This may be due to the small
number of participants and the short time interval
(24 weeks) between biopsies. Nevertheless, the improve-
ment depicted in our figures from skin histology may
suggest a potentially modifying role of RTX in the patho-
logical process of skin fibrosis in SSc.
Two recent uncontrolled studies have explored the
potential clinical efficacy of a single cycle of RTX in SSc.
In the study by Smith et al. [25], clinical and histological
improvement of skin fibrosis was observed at 24 weeks
following RTX treatment and in the study by Lafyatis et al.
[26], a significant reduction of the myofibroblast score in
skin biopsies of RTX-treated patients was reported. These
data are in agreement with ours and suggest that RTX
may favourably affect skin fibrosis in SSc. Lung function
tests at 24 weeks were stable in both the previously
mentioned studies. We should note, however, that only
7 out of 15 patients in the study by Lafyatis et al. and
5 out of 8 patients in the study by Smith et al. had
evidence of mild ILD (since patients with significant ILD
were excluded), whereas in our study the presence of ILD
was one of the inclusion criteria (and most patients
had significant ILD). Furthermore, our study is the first in
the literature to report lung function parameters at 1 year
following RTX administration and the first to report the
effects of two consecutive cycles of RTX on lung function
and skin thickening in SSc.
Although RTX has been successfully introduced lately in
the treatment of various autoimmune diseases, its exact
mechanism of action is not completely understood.
Pathogenesis of SSc is largely unknown but the results
of the present study indicate that B cells may play a role
and RTX may have a favourable effect on the disease
process. RTX targets B cells that are present in skin
biopsies of patients with scleroderma [40] and are the
source of autoantibodies, some of which may contribute
to pathogenesis [41]. In addition, it has become clear that
apart from peripheral B-cell depletion, RTX indirectly
affects other immune cells such as T cells [42, 43],
which have been implicated in SSc pathogenesis as well
[44, 45]. In our study, improvement of skin fibrosis was
more commonly encountered in patients with evidence
of B-cell depletion in the skin, indirectly supporting a
potential role of B cells in SSc. Although our data are
preliminary, we may propose that the number of infiltrating
B cells in the dermis, as assessed by skin biopsy, could
serve as a marker of response to RTX therapy in patients
with SSc.
Our study has several potential limitations. The first one
is the small number of patients recruited, which does not
provide the study with sufficient statistical power to prove
efficacy. Indeed, this is a proof-of-principle study that was
performed in order to obtain preliminary data regarding
the effect of RTX on a limited number of patients with
SSc. We designed the study as an open label randomized
controlled one, so that we can compare the results of the
RTX-treated patients with a similarly affected control
group of patients receiving standard treatment and care.
An additional limitation is that most patients had long-
standing disease and had received various forms of
immunosuppressive treatment in the past. The patients
enrolled in our study are heterogeneous in terms of
disease duration, severity and previous treatments.
Ideally, one should have recruited patients with early
disease and with no previous exposure to other forms of
immunosuppressive treatment, but this approach might
be hampered by disease rarity. Yet another limitation is
that patients in both the RTX and the control group
received several concurrent immune-based therapies
and even though they were on the same treatment for
a significant amount of time prior to enrolment, one
cannot rule out the possibility that these therapies
contributed to the outcomes reported in this study.
Furthermore, improvement of skin fibrosis may associate
with the natural course of the disease; nevertheless,
improvement of skin fibrosis was seen only in our
RTX-treated group and not in the control group.
We report herein the results of a controlled study
evaluating the efficacy of RTX in patients with SSc and
SSc-associated ILD. Our data, although preliminary and
on a small cohort, indicate a possible disease-modifying
role of RTX in SSc, particularly in SSc-associated lung
disease. However, in SSc treatment several therapeutic
agents have shown some efficacy in small-scale studies
but failed to do so in larger scale studies. Taking into
consideration the limitations of the present study, definite
conclusions should not be drawn. Nevertheless, our data
could serve as a good starting point for the design of
larger scale, multicentre studies with longer evaluation
periods and especially in earlier stages of the disease.
Rheumatology key messages
. Several lines of evidence indicate a potential role of
B cells in the pathogenesis of scleroderma.
. RTX may improve lung function in patients with
SSc.
. Large-scale, multicentre studies are needed to eval-
uate the potential efficacy of RTX in scleroderma.
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